| 1 |
32892505 | Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays. | 2021 Feb |
1 |
| 2 |
33034200 | Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates. | 2020 Jan-Dec |
1 |
| 3 |
30086574 | Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery. | 2018 Sep |
1 |
| 4 |
30194803 | Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology. | 2018 Nov |
2 |
| 5 |
26377606 | The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin. | 2016 Jun 5 |
1 |
| 6 |
26607136 | Role of exosite binding modulators in the inhibition of Fxa by TFPI. | 2016 Mar |
3 |
| 7 |
27566697 | Modulation of factors involved in placental haemostasis and angiogenesis by low-molecular-weight-heparins. | 2016 Nov |
1 |
| 8 |
25525049 | Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model. | 2015 Apr |
2 |
| 9 |
24266905 | Early heparin administration attenuates tissue factor-mediated thrombin generation during simulated cardiopulmonary bypass. | 2014 Jan |
7 |
| 10 |
23320987 | TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. | 2013 Jan 15 |
1 |
| 11 |
22302552 | Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients. | 2012 Feb 14 |
4 |
| 12 |
19959490 | Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates. | 2010 Feb |
1 |
| 13 |
20592020 | C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. | 2010 Sep 3 |
2 |
| 14 |
20880110 | Novel interactions between UFH and TFPI in children. | 2010 Nov |
7 |
| 15 |
21162606 | Bemiparin: pharmacological profile. | 2010 Dec 14 |
1 |
| 16 |
19218095 | Regulation of thrombin generation by TFPI in plasma without and with heparin. | 2009 Mar |
2 |
| 17 |
19285275 | Heparanase coagulation and cancer progression. | 2009 Mar |
2 |
| 18 |
19731406 | Tissue factor pathway inhibitor release and depletion by sulodexide in humans. | 2009 |
2 |
| 19 |
19736157 | A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. | 2009 Aug |
2 |
| 20 |
18160611 | Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid--anchored forms of tissue factor pathway inhibitor. | 2008 Jul |
9 |
| 21 |
18261960 | Expression of tissue factor pathway inhibitor by endothelial cells and platelets. | 2008 Feb |
1 |
| 22 |
18645924 | Heparanase, tissue factor, and cancer. | 2008 Mar |
1 |
| 23 |
18716314 | Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin. | 2008 Oct |
2 |
| 24 |
16824584 | Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. | 2007 |
6 |
| 25 |
16919311 | Relative quantification of glycosaminoglycan-induced upregulation of TFPI-mRNA expression in vitro. | 2007 |
5 |
| 26 |
17376263 | [Highlighting the potential of heparin in the treatment of sepsis in view of failure of KyberSept and OPTIMIST projects]. | 2007 Mar |
2 |
| 27 |
16461305 | Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. | 2006 Feb |
1 |
| 28 |
16520718 | Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. | 2006 Mar |
4 |
| 29 |
16689752 | Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. | 2006 May |
9 |
| 30 |
15678271 | Comparative tissue factor pathway inhibitor release potential of heparins. | 2005 Jan |
8 |
| 31 |
15876997 | Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. | 2005 Mar |
2 |
| 32 |
15351861 | Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. | 2004 Sep |
1 |
| 33 |
15570242 | Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. | 2004 Nov |
8 |
| 34 |
15815881 | Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor. | 2004 Dec |
1 |
| 35 |
12519315 | Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria. | 2003 Jan |
6 |
| 36 |
12624625 | Local tissue factor pathway inhibitor release in the human forearm. | 2003 Mar |
3 |
| 37 |
12801846 | Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells. | 2003 Jun |
5 |
| 38 |
12808176 | Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. | 2003 Jul |
10 |
| 39 |
12856386 | Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. | 2003 Jul |
2 |
| 40 |
12893029 | Tissue factor pathway inhibitor production by human proximal tubular epithelial cells in culture. | 2003 May 1 |
3 |
| 41 |
14574072 | Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor. | 2003 Feb |
2 |
| 42 |
14675115 | Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days. | 2003 Dec |
1 |
| 43 |
11772005 | Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. | 2002 Jan 8 |
4 |
| 44 |
11804978 | Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. | 2002 Jan 22 |
1 |
| 45 |
11848461 | Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. | 2002 Jan |
1 |
| 46 |
11854880 | Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. | 2002 Feb |
4 |
| 47 |
12021535 | Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients. | 2002 May |
1 |
| 48 |
12028043 | Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. | 2002 Jun |
1 |
| 49 |
12063117 | Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI). | 2002 Jun 18 |
4 |
| 50 |
12482841 | Characterization of the association of tissue factor pathway inhibitor with human placenta. | 2002 Dec 1 |
3 |